10 Best Genomics Stocks To Buy Right Now

2. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Upside potential as of November 14: 64.11%

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is an industry leader in antisense technology for drug discovery and development. Cardiovascular, metabolic, neurological, and uncommon disorders are among the many ailments that are the focus of its extensive clinical and preclinical pipeline. Spinraza was introduced to the market by Ionis and partner Biogen in 2016 as a treatment for spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen introduced the ALS medication Qalsody. Through its cardiovascular-focused subsidiary Akcea, Ionis introduced two more medications to the market: Waylivra (Europe, 2019) and Tegsedi (2018), a medication for ATTR amyloidosis. In 2024, Ionis and AstraZeneca introduced Wainua, a medication for polyneuropathy.

As a pioneer in RNA-based treatments, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’ Spinraza, a medication for spinal muscular atrophy sold by partner Biogen, is the first to become a blockbuster. Gene editing and gene therapy pipelines at several companies, as well as RNA interference technologies from Alnylam, Arrowhead, and Novo Nordisk (Dicerna), pose a serious threat to the company’s antisense oligonucleotide, or ASO, technology. However, Ionis has created a vast pipeline of potential new medications that are quickly approaching the market.

The UK’s approval of eplontersen resulted in substantial financial gains and a favorable EMA opinion. Furthermore, a strong growth trajectory is suggested by the expected approval of olezarsen for familial chylomicronemia syndrome and the forthcoming data releases for several other medications in their late-stage trials.

Based on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’ recent advances and financial performance, Joseph Stringer rated it as a Buy on November 7. Even though the company’s total revenues were just less than Stringer’s own prediction, they nevertheless exceeded the mainstream projections. Ionis has also achieved great strides in its clinical pipeline, especially with the alignment on the design of the Phase 3 trial for its medicine ION582, which targets Angelman Syndrome and is anticipated to start in the first half of 2025.

Furthermore, by the end of 2024, Ionis expects significant future milestones, including the possible approval and introduction of Olezarsen in the treatment of familial chylomicronemia syndrome (FCS). The revised year-end cash estimate of $2.2 billion further demonstrates the company’s strong financial standing. Together, these factors support Stringer’s Buy recommendation for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).